Bioverativ
225 Second Avenue
Waltham
Massachusetts
02451
United States
Tel: 781-663-4400
Website: https://www.bioverativ.com/
About Bioverativ
Launching in 2017, Bioverativ will build on Biogen’s leading hemophilia business to transform the lives of people with hemophilia and other rare blood disorders.YEAR FOUNDED:
2017
LEADERSHIP:
CEO: John Cox
66 articles about Bioverativ
-
The difference between the salaries paid to top executives and the median income earned by rank and file employees has been a sore subject for many years and has served as a wedge political issue in recent elections.
-
Biogen saw a strong first quarter with 11 percent growth in revenues to $3.1 billion, which were spurred by gains in spinal muscular atrophy (SMA) treatment Spinraza and multiple sclerosis treatment Tecfidera.
-
Bioverativ Highlights the Impact of Humanitarian Aid in Hemophilia
4/17/2018
More than 15,000 people with hemophilia in 40 developing countries have already been treated following Bioverativ and Sobi’s unprecedented donation of factor therapy to the WFH Humanitarian Aid Program
-
While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
-
Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease
3/6/2018
Significant unmet need for a treatment for cold agglutinin disease, a chronic rare blood disease that can result in life-threatening events like stroke.
-
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
-
The deal includes a licence to use OXB's LentiVector Enabled technology and access to its industrial-scale manufacturing technology.
-
Bioverativ Reports Fourth Quarter and Full Year 2017 Performance
2/14/2018
As of December 31, 2017, Bioverativ had $436.5 million in cash and cash equivalents and no debt.
-
Bioverativ Release: Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A
2/14/2018
Bioverativ today announced the publication of a retrospective analysis investigating the use of ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] for immune tolerance induction (ITI).
-
It took more than 8 months and a series of sweetened offers, but Sanofi was able to close their $11.6B deal to buy Bioverativ without triggering an auction.
-
Sanofi Commences Tender Offer for Acquisition of Bioverativ
2/8/2018
The Offer is being made pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018.
-
The SEC filed a suit against “one or more unknown traders” while it seeks to identify the perpetrators.
-
The deal has Sanofi paying $105 per share in cash.
-
M&A Fury Hits and It's Only Just January
1/17/2018
We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals. -
Bioverativ to Report Fourth Quarter and Year-End 2017 Financial Results on February 13, 2018
1/17/2018
On Wednesday, February 14, 2018, at 8:00 a.m. EST, the company will host a live webcast with Bioverativ management.
-
Bioverativ Announces 2018 Annual Meeting of Stockholders
12/27/2017
Bioverativ announced today that its 2018 Annual Meeting of Stockholders has been scheduled for April 25, 2018.
-
7 Hot Biotech Investing Bets
12/20/2017
We now turn to six MoneyShow.com contributors for their best ideas in biotechnology, a sector with both high risk and the potential for high rewards. -
Bioverativ’s Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) Patients
12/12/2017
Bioverativ presented data demonstrating that BIVV009, its first-in-class monoclonal antibody currently in Phase 3 clinical development for the treatment of cold agglutinin disease (CAgD), was generally well tolerated, rapidly halted hemolysis, and improved anemia in six of six severely anemic primary CAgD patients in a Phase 1b clinical trial.
-
Bioverativ Release: New Data Show Extended Prophylactic Dosing With ALPROLIX Provides Safe and Effective Protection in People With Severe Hemophilia B
12/12/2017
The analysis is being presented in a poster session at the 59th Annual Meeting of the American Society of Hematology (ASH).
-
Bioverativ Release: Study Shows Weekly Prophylactic Treatment With ELOCTATE Resulted in Bleed Protection and Target Joint Resolution in People With Hemophilia A
12/11/2017
The analysis is being presented today in a poster session at the 59th Annual Meeting of the American Society of Hematology.